Condition: Lung Cancer (Non-Small Cell) · Sponsor: Guangdong Association of Clinical Trials
Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor the KRAS G12C mutation. Treatment Regimen: All enrolled subjects will receive IBI351 combined with cetuximab β injection. Treatment will continue until disease progression (as assessed by the investigator per RECIST 1.1 criteria) or the occurrence of intolerable toxicity. Primary Endpoint: Objective Response Rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary Endpoints: Disease Control Rate (DCR), Time to Response (TTR), Progression-Free Survival (PFS), and Overall Survival (OS) , and safety.
This description comes directly from the study's public registry record.
Qing Zhou, PhD · +86 20 83827812 · gzzhouqing@126.com
Always discuss trial participation with your own doctor first.
| Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, | Guangzhou, Guangdong, China | Recruiting |
| Chinese PLA General Hospital | Beijing, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, China | Recruiting |
| The first affiliated hospital of nanchang university | Nanchang, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| Affiliated Tumor Hospital of Guangxi Medical University | Nanning, China | Not Yet Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07198841